Trial
NCT02525692
Oral ONC201 in Adult Recurrent Glioblastoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
Oncoceutics, Inc.
Condition
Glioblastoma
Intervention
Dordaviprone (ONC201)
Why stopped
The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-24